New funding for target discovery related to SynGAP1-associated non-syndromic intellectual disability
We are excited to be starting a new project on SynGAP thanks to support from Leon & friends e.V.
SynGAP is a protein that reduces the activity of Ras-GTPases, which are important in regulating the ERK group of MAP kinases and synaptic connectivity. Mutations in the SynGAP1-gene can cause a non-syndromic intellectual disability (NSID) disorder that often includes epilepsy. Our project aims to make use of our recently developed high-throughout physiology pipeline to identify RasGEF proteins, the RasGTPase activators, that counteract the neuronal signalling affected by reduced SynGAP levels. These RasGEFs could potentially be druggable targets relevant for drug discovery approaches to treat SynGAP-associated NSID.
Last updated on March 5, 2025
Recent Posts
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026